Reactivation of M. tuberculosis infection in trans-membrane tumour necrosis factor mice

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Dambuza, Ivy ^a   Keeton, Roanne ^a   Allie, Nasiema ^a   Hsu, Nai Jen ^a   Randall, Philippa ^a   Sebesho, Boipelo ^a   Fick, Lizette ^a   Quesniaux, Valerie J F ^b,c   Jacobs, Muazzam ^a,d  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b CNRS   (France)

^c UNIVERSITÉ D'ORLÉANS   (France)

^d NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P70; ISONIAZID; RIFAMPICIN; SOLUBLE TUMOR NECROSIS FACTOR; TRANSMEMBRANE TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CYTOKINE; INDUCIBLE NITRIC OXIDE SYNTHASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACILLI; BACTERIAL GROWTH; BACTERIAL IMMUNITY; CONTROLLED STUDY; GRANULOMA; HOST SUSCEPTIBILITY; IMMUNE RESPONSE; LEUKOCYTE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTEIN EXPRESSION; TUBERCULOSIS; WILD TYPE; ANIMAL; C57BL MOUSE; CELL MEMBRANE; DISEASE COURSE; DISEASE MODEL; DRUG EFFECT; ENZYMOLOGY; GROWTH, DEVELOPMENT AND AGING; INFLAMMATION; LUNG; LYMPHOCYTE; MACROPHAGE; METABOLISM; MICROBIOLOGY; PATHOLOGY; PHYSIOLOGY;

BACILLI (CLASS); BACTERIA (MICROORGANISMS); CORYNEBACTERINEAE; MUS; MYCOBACTERIUM TUBERCULOSIS;

ANIMALS; CELL MEMBRANE; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GRANULOMA; INFLAMMATION; LUNG; LYMPHOCYTES; MACROPHAGES; MICE; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; NITRIC OXIDE SYNTHASE TYPE II; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 81455144567     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025121     Document Type: Article

References (58)

1. WHO (2010) GLOBAL TURCULOSIS CONTROL.
2. Scanga CA, Mohan VP, Joseph H, Yu K, Chan J, et al. (1999) Reactivation of latent tuberculosis: variations on the Cornell murine model. Infect Immun 67: 4531-4538.
3. Manabe YC, Kesavan AK, Lopez-Molina J, Hatem CL, Brooks M, et al. (2008) The aerosol rabbit model of TB latency, reactivation and immune reconstitution inflammatory syndrome. Tuberculosis (Edinb) 88: 187-196.
4. Van Rhijn I, Godfroid J, Michel A, Rutten V, (2008) Bovine tuberculosis as a model for human tuberculosis: advantages over small animal models. Microbes Infect 10: 711-715.
5. Wayne LG, Hayes LG, (1996) An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 64: 2062-2069.
6. Bean AG, Roach DR, Briscoe H, France MP, Korner H, et al. (1999) Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 162: 3504-3511.
7. Kaneko H, Yamada H, Mizuno S, Udagawa T, Kazumi Y, et al. (1999) Role of tumor necrosis factor-alpha in Mycobacterium-induced granuloma formation in tumor necrosis factor-alpha-deficient mice. Lab Invest 79: 379-386.
8. Smith S, Liggitt D, Jeromsky E, Tan X, Skerrett SJ, et al. (2002) Local role for tumor necrosis factor alpha in the pulmonary inflammatory response to Mycobacterium tuberculosis infection. Infect Immun 70: 2082-2089.
9. Chakravarty SD, Zhu G, Tsai MC, Mohan VP, Marino S, et al. (2008) Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungs. Infect Immun 76: 916-926.
10. Botha T, Ryffel B, (2003) Reactivation of latent tuberculosis infection in TNF-deficient mice. J Immunol 171: 3110-3118.
11. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345: 1098-1104.
12. Dimakou K, Papaioannides D, Latsi P, Katsimboula S, Korantzopoulos P, et al. (2004) Disseminated tuberculosis complicating anti-TNF-alpha treatment. Int J Clin Pract 58: 1052-1055.
13. Desai SB, Furst DE, (2006) Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 20: 757-790.
14. Sichletidis L, Settas L, Spyratos D, Chloros D, Patakas D, (2006) Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 10: 1127-1132.
15. Harris J, Keane J, (2010) How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol 161: 1-9.
16. Bruns H, Meinken C, Schauenberg P, Harter G, Kern P, et al. (2009) Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest 119: 1167-1177.
17. Grell M, (1995) Tumor necrosis factor (TNF) receptors in cellular signaling of soluble and membrane-expressed TNF. J Inflamm 47: 8-17.
18. Dambuza I, Allie N, Fick L, Johnston N, Fremond C, et al. (2008) Efficacy of membrane TNF mediated host resistance is dependent on mycobacterial virulence. Tuberculosis (Edinb) 88: 221-234.
19. Fremond C, Allie N, Dambuza I, Grivennikov SI, Yeremeev V, et al. (2005) Membrane TNF confers protection to acute mycobacterial infection. Respir Res 6: 136.
20. Saunders BM, Tran S, Ruuls S, Sedgwick JD, Briscoe H, et al. (2005) Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection. J Immunol 174: 4852-4859.
21. Allie N, Alexopoulou L, Quesniaux VJ, Fick L, Kranidioti K, et al. (2008) Protective role of membrane tumour necrosis factor in the host's resistance to mycobacterial infection. Immunology 125: 522-534.
22. Steed PM, Tansey MG, Zalevsky J, Zhukovsky EA, Desjarlais JR, et al. (2003) Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science 301: 1895-1898.
23. Spohn G, Guler R, Johansen P, Keller I, Jacobs M, et al. (2007) A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J Immunol 178: 7450-7457.
24. Olleros ML, Vesin D, Lambou AF, Janssens JP, Ryffel B, et al. (2009) Dominant-negative tumor necrosis factor protects from Mycobacterium bovis Bacillus Calmette Guerin (BCG) and endotoxin-induced liver injury without compromising host immunity to BCG and Mycobacterium tuberculosis. J Infect Dis 199: 1053-1063.
25. Zalevsky J, Secher T, Ezhevsky SA, Janot L, Steed PM, et al. (2007) Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J Immunol 179: 1872-1883.
26. Marino MW, Dunn A, Grail D, Inglese M, Noguchi Y, et al. (1997) Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci U S A 94: 8093-8098.
27. Ruuls SR, Hoek RM, Ngo VN, McNeil T, Lucian LA, et al. (2001) Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity 15: 533-543.
28. Jacobs M, Marino MW, Brown N, Abel B, Bekker LG, et al. (2000) Correction of defective host response to Mycobacterium bovis BCG infection in TNF-deficient mice by bone marrow transplantation. Lab Invest 80: 901-914.
29. Garcia I, Guler R, Vesin D, Olleros ML, Vassalli P, et al. (2000) Lethal Mycobacterium bovis Bacillus Calmette Guerin infection in nitric oxide synthase 2-deficient mice: cell-mediated immunity requires nitric oxide synthase 2. Lab Invest 80: 1385-1397.
30. McCune RM, Feldmann FM, Lambert HP, McDermott W, (1966) Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J Exp Med 123: 445-468.
31. Koo MS, Manca C, Yang G, O'Brien P, Sung N, et al. Phosphodiesterase 4 Inhibition Reduces Innate Immunity and Improves Isoniazid Clearance of Mycobacterium tuberculosis in the Lungs of Infected Mice. PLoS One pp. e17091.
32. Algood HM, Lin PL, Flynn JL, (2005) Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis 41 (Suppl 3): S189-193.
33. Mohan VP, Scanga CA, Yu K, Scott HM, Tanaka KE, et al. (2001) Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 69: 1847-1855.
34. Chan J, Tanaka K, Carroll D, Flynn J, Bloom BR, (1995) Effects of nitric oxide synthase inhibitors on murine infection with Mycobacterium tuberculosis. Infect Immun 63: 736-740.
35. Flynn JL, Scanga CA, Tanaka KE, Chan J, (1998) Effects of aminoguanidine on latent murine tuberculosis. J Immunol 160: 1796-1803.
36. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, et al. (1993) Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 178: 2243-2247.
37. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, et al. (1993) An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 178: 2249-2254.
38. Cooper AM, Roberts AD, Rhoades ER, Callahan JE, Getzy DM, et al. (1995) The role of interleukin-12 in acquired immunity to Mycobacterium tuberculosis infection. Immunology 84: 423-432.
39. Feng CG, Jankovic D, Kullberg M, Cheever A, Scanga CA, et al. (2005) Maintenance of pulmonary Th1 effector function in chronic tuberculosis requires persistent IL-12 production. J Immunol 174: 4185-4192.
40. Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, et al. (1995) Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2: 561-572.
41. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P, (1989) The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 56: 731-740.
42. Roach DR, Bean AG, Demangel C, France MP, Briscoe H, et al. (2002) TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 168: 4620-4627.
43. Florido M, Appelberg R, (2007) Characterization of the deregulated immune activation occurring at late stages of mycobacterial infection in TNF-deficient mice. J Immunol 179: 7702-7708.
44. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, et al. (1991) Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. Embo J 10: 4025-4031.
45. Probert L, Plows D, Kontogeorgos G, Kollias G, (1995) The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice. Eur J Immunol 25: 1794-1797.
46. Schottelius AJ, Moldawer LL, Dinarello CA, Asadullah K, Sterry W, et al. (2004) Biology of tumor necrosis factor-alpha- implications for psoriasis. Exp Dermatol 13: 193-222.
47. Agnholt J, Dahlerup JF, Kaltoft K, (2003) The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures. Cytokine 23: 76-85.
48. Mitoma H, Horiuchi T, Tsukamoto H, (2004) Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-alpha. Gastroenterology 126: 934-935; author reply 935-936.
49. Mitoma H, Horiuchi T, Hatta N, Tsukamoto H, Harashima S, et al. (2005) Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 128: 376-392.
50. Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, et al. (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301: 418-426.
51. Olleros ML, Guler R, Vesin D, Parapanov R, Marchal G, et al. (2005) Contribution of transmembrane tumor necrosis factor to host defense against Mycobacterium bovis bacillus Calmette-guerin and Mycobacterium tuberculosis infections. Am J Pathol 166: 1109-1120.
52. Ehlers S, (2003) Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF. Ann Rheum Dis 62 (Suppl 2): ii37-42.
53. Anolik JH, Ravikumar R, Barnard J, Owen T, Almudevar A, et al. (2008) Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J Immunol 180: 688-692.
54. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, et al. (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50: 1400-1411.
55. Lin PL, Myers A, Smith L, Bigbee C, Bigbee M, et al. Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model. Arthritis Rheum 62: 340-350.
56. Iliopoulos A, Psathakis K, Aslanidis S, Skagias L, Sfikakis PP, (2006) Tuberculosis and granuloma formation in patients receiving anti-TNF therapy. Int J Tuberc Lung Dis 10: 588-590.
57. Johnson CM, Cooper AM, Frank AA, Orme IM, (1998) Adequate expression of protective immunity in the absence of granuloma formation in Mycobacterium tuberculosis-infected mice with a disruption in the intracellular adhesion molecule 1 gene. Infect Immun 66: 1666-1670.
58. Saliu OY, Sofer C, Stein DS, Schwander SK, Wallis RS, (2006) Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 194: 486-492.